CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
基于嵌合抗原受体的疗法在癌症以外的应用
英文原题：Chimeric antigen receptor-based therapies beyond cancer.
查看英文原题
Chimeric antigen receptor-based therapies beyond cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
过继性细胞转移（ACT）疗法在嵌合抗原受体（CAR）技术出现后，在免疫治疗领域重新引起了人们的兴趣。这一免疫学突破需要对免疫细胞进行工程化改造，使其表达一种人工表面蛋白受体，用于抗原特异性识别，并与一个细胞内蛋白结构域偶联以执行细胞激活功能。基于CAR的ACT已成功解决了一些血液系统恶性肿瘤，预计其他肿瘤也可能很快受益于这种方法。然而，CAR技术的潜力使得其他免疫介导的疾病也开始从中获益。本综述将聚焦于基于CAR的ACT在肿瘤学以外的治疗领域，如感染、过敏、自身免疫、移植和纤维化修复。在此，我们讨论该方面临床前和临床研究的结果与局限性。
展开英文摘要原文
Adoptive cell transfer (ACT) therapies have gained renewed interest in the field of immunotherapy following the advent of chimeric antigen receptor (CAR) technology. This immunological breakthrough requires immune cell engineering with an artificial surface protein receptor for antigen-specific recognition coupled to an intracellular protein domain for cell activating functions. CAR-based ACT has successfully solved some hematological malignancies, and it is expected that other tumors may soon benefit from this approach.
However, the potential of CAR technology is such that other immune-mediated disorders are beginning to profit from it. This review will focus on CAR-based ACT therapeutic areas other than oncology such as infection, allergy, autoimmunity, transplantation, and fibrotic repair.
Herein, we discuss the results and limitations of preclinical and clinical studies in that regard.
论文信息
- 作者
- Velasco-de Andrés M、Muñoz-Sánchez G、Carrillo-Serradell L、Gutiérrez-Hernández MDM、Català C、Isamat M、Lozano F
- 单位
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.Spain
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- European journal of immunology2023 Mar
- 原文标识
- PubMed 36649259 · DOI 10.1002/eji.202250184